Executive Director, Biologics DMPK & Translational Sciences

Odyssey Therapeutics•Boston, MA

5h•$199,986 - $375,974

About The Position

The Executive Director, Biologics DMPK & Translational Sciences will provide enterprise-wide technical and scientific leadership for the discovery-to-development transition of Odyssey's biologics portfolio, with ultimate accountability for the strategy, organization, and execution of biologics DMPK (drug metabolism and pharmacokinetics) and translational sciences. Reporting to the SVP, Nonclinical Development and serving as a key member of the Nonclinical Development leadership team, this individual will partner closely with Protein Therapeutics, Discovery, Nonclinical Safety Assessment, Biologics CMC, Regulatory Affairs, and Clinical Development, and will represent biologics DMPK and translational strategy to senior leadership and governance forums as candidates advance toward IND-ready, clinically de-risked assets. This is a high-visibility leadership role for an accomplished scientific leader who thrives in a fast-moving, multi-modality environment and wants to build and scale the organization, capabilities, and strategic influence of biologics development as Odyssey grows its biologics portfolio.

Requirements

Ph.D. (or equivalent) in pharmacokinetics, pharmacology, biochemistry, pharmaceutical sciences, or a related discipline.
A minimum of 15 years of biopharmaceutical industry experience, with a substantial portion focused on the PK/DMPK and translational characterization of biologics (e.g., monoclonal antibodies, Fc fusion proteins, fusion protein biologics, bispecifics, or related modalities), including significant experience leading people managers and building organizational capability.
Demonstrated expertise leading the discovery-to-nonclinical development transition of biologics, including candidate developability assessment, IND-enabling strategy, and successful candidate-to-clinic progression.
Deep expertise in biologics DMPK and translational sciences, including target-mediated disposition, immunogenicity/ADA assessment, large-molecule bioanalysis (ligand-binding assays and/or LC/MS), and PK/PD modeling and simulation (e.g., Phoenix/WinNonlin, MATLAB/SimBiology, or comparable tools).
Track record of first-in-human dose prediction and translational strategy supporting successful IND submissions.
Demonstrated track record leading and developing multi-layered scientific organizations, including people managers, and managing CROs/external partners in a matrixed environment.
Strong record of cross-functional and executive leadership, with the ability to translate complex DMPK and translational data into clear, actionable recommendations for project teams, governance bodies, senior leadership, and the Board.
Excellent written and verbal communication; a collaborative, science-driven leadership style aligned with Odyssey's culture of rigor, integrity, and patient focus.

Nice To Haves

Experience in immunology, inflammation, and/or oncology programs is highly desirable.

Responsibilities

Lead the discovery-to-nonclinical development transition strategy for Odyssey's biologics portfolio, ensuring candidates are advanced with the right developability, PK/PD, and translational data packages to support confident candidate nomination and IND filings.
Define and own the biologics DMPK strategy across the portfolio, including in vitro and in vivo PK characterization, target-mediated drug disposition assessment, immunogenicity/anti-drug-antibody (ADA) impact evaluation, and bioanalytical method strategy for large molecules.
Drive translational science and PK/PD modeling to answer critical development questions, establish exposure–response relationships, and generate robust first-in-human dose projections and biomarker strategies.
Serve as the most senior biologics development subject-matter expert and a trusted advisor to executive leadership and governance bodies, influencing molecule design, candidate selection, and program direction through expert interpretation of DMPK and translational data.
Partner with Discovery and Protein Therapeutics to embed developability and PK considerations into early molecule engineering and lead optimization for fusion proteins, Fc fusions, and antibody-based modalities.
Work closely and in partnership with preclinical toxicology to design and execute DRF and GLP toxicology program.
Design, oversee, and interpret nonclinical PK, pharmacology, and IND-enabling studies, including coordination of internal work and external CROs to ensure high-quality, on-time, regulatory-compliant deliverables.
Own authorship and review of DMPK and translational sections of regulatory documents (IND, IB, briefing documents), and lead health authority interactions on DMPK and translational matters.
Build, mentor, and scale a high-performing biologics development and DMPK organization — including people managers and senior scientists — and own the function's strategy, budget, and resourcing, establishing fit-for-purpose processes, capabilities, and ways of working as Odyssey grows.
Represent biologics DMPK and translational sciences in business development and licensing diligence, scientific advisory board interactions, and other external partnerships, providing executive-level scientific input to portfolio and investment decisions.
Stay current with advances in biologics DMPK, translational science, and regulatory expectations, bringing innovative and efficient approaches to the portfolio.